<DOC>
	<DOCNO>NCT02392208</DOCNO>
	<brief_summary>Chronic Kidney Disease Stage 5 ( CKD5 ) patient receive maintenance hemodialysis increase risk develop bloodstream infection . Vancomycin traditionally use first-line therapy treat infection , emergence less-susceptible bacterial strain necessitate consideration alternative antibiotic therapy . Telavancin new antibiotic broad-spectrum antimicrobial activity gram-positive bacteria , include vancomycin-intermediate staphylococcus aureus . While dose recommendation telavancin available patient normal kidney function , publish recommendation CKD5 patient receive hemodialysis . A pharmacokinetic study need characterize pharmacokinetic parameter telavancin patient determine extent drug removal hemodialysis establish dose recommendation CKD5 patient maintenance hemodialysis .</brief_summary>
	<brief_title>Effect Dialysis Pharmacokinetics Telavancin Patients With Chronic Kidney Disease Stage 5</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>≥ 18 year age Within 50 150 % ideal body weight great 40 kg CKD5 receive maintenance hemodialysis ≥ 3 month Creatinine Clearance estimate &lt; 10 mL/min Not receive telavancin within past month No concurrent illness evidence infection Able give inform consent Prestudy Hemoglobin &lt; 9.0 g/dL Plasma Albumin &lt; 2.5 g/dL Pregnancy Breastfeeding QTc interval &gt; 470 msec EKG obtain within last 6 month Receiving concomitant QT prolong agent Receiving warfarin low molecular weight heparin product Known allergy telavancin vancomycin Unstable blood pressure control Need routine large fluid removal dialysis ( &gt; 4 liter ) Diagnosis liver disease Child Pugh score C high Dialysis isolation requirement due Hepatitis B Participating concurrently another investigational drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>telavancin</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>ESRD</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>dialysis</keyword>
	<keyword>Vibativ</keyword>
</DOC>